Full-Time

Vice President

Clinical Pharmacology

Amylyx Pharmaceuticals

Amylyx Pharmaceuticals

51-200 employees

Biopharmaceutical company developing neurodegenerative therapies

Compensation Overview

$304k - $342k/yr

Cambridge, MA, USA

Remote

Not considering applicants from AK, AZ, HI, MI, TN; travel to Cambridge, MA several times per year.

Category
Biology & Biotech (2)
,
Requirements
  • PhD, PharmD, MD, or equivalent training in pharmacokinetics, pharmaceutical sciences, or related disciplines
  • Minimum 12 years of experience within the pharmaceutical and biotechnology industry with 5+ years' direct experience in Clinical Pharmacology
  • Experience in an array of molecules including biologics, small molecules and gene therapy
  • Demonstrated experience in writing, presenting, and discussing clinical pharmacology with regulatory authorities as well as other external and internal stakeholders
  • Strong analytical skills and ability to interpret complex clinical data sets as well as deep understanding of individual patient data coupled with excellent written and verbal communication skills
  • Ability to work in cross-functional teams and manage multiple projects, engaging subject matter experts across functions to drive the execution of programs
  • Strong technical proficiency in PK analysis (NCA and PopPK)
  • Ability to work with an elevated level of integrity, accuracy, and attention to detail, while executing corporate objectives and goals
  • Entrepreneurial, enjoys working in a fast-paced, small-company environment
Responsibilities
  • Serve as the clinical pharmacologist for the company across all clinical programs, providing strategic and scientific input from preclinical development through Phase 3 trials
  • Lead the Clinical Pharmacology team accountability for the clinical pharmacology strategy for Amylyx' development portfolio from pre-IND through and post approval, including design and implementation of program specific clinical pharmacology studies, data analysis, internal decision points, and external regulatory interactions
  • Integrate clinical pharmacology knowledge with a broad understanding of and collaboration with related disciplines such as clinical, statistics, regulatory, nonclinical ADME, toxicology to support and impact development decisions
  • Ensure appropriate PK, PD and PK/PD data analyses (including population PK, PK/PD modeling and simulation) are conducted for each study/program.
  • Collaborates with toxicologist and preclinical pharmacology scientists to design, analyze, interpret, and report preclinical PK and translational PK/PD studies to support candidate selection and IND filing, including human PK prediction to support starting dose and dose escalation schemes for first-in-human studies
  • Ensure adherence to agreed timelines and budgets to insure prompt and accurate execution of deliverables from clinical pharmacology studies and programs
  • Serves as the clinical Pharmacology expert across study and program teams
  • Develops and implements new clinical pharmacology approaches to processes and clinical studies that impact development programs
  • Contributes to program strategy, study design, protocol preparation, study execution, data review/analysis, study reports and regulatory document preparation
  • Works closely with research and development teams and provides input into assay development, CRO selection and CRO management. Leads method development, method qualification, method validation activities as SME and sponsor monitor, as assigned.
  • Represents nonclinical and clinical pharmacology during meetings and discussions with regulatory authorities
  • Creates or guides nonclinical and clinical pharmacology summary documents
  • Reviews literature and peer-reviewed publications to keep apprised of global regulatory developments in clinical pharmacology; Authors/ reviews manuscripts for submission to peer-reviewed journals
Amylyx Pharmaceuticals

Amylyx Pharmaceuticals

View

Amylyx Pharmaceuticals develops treatments for neurodegenerative diseases, with a focus on ALS and Alzheimer's disease. Its main asset is AMX0035, currently in clinical trials, including the CENTAUR study for ALS and the PEGASUS study for late mild cognitive impairment or early dementia due to Alzheimer’s disease. The company advances products through rigorous, randomized, double-blind, placebo-controlled trials to demonstrate safety and efficacy before pursuing commercialization. In addition to research, Amylyx engages in awareness and community campaigns to support patients, caregivers, and researchers. The company aims to bring validated therapies to market to improve patient outcomes and generate revenue by selling treatments to healthcare providers and patients.

Company Size

51-200

Company Stage

IPO

Headquarters

Cambridge, Massachusetts

Founded

2013

Simplify Jobs

Simplify's Take

What believers are saying

  • LUCIDITY Phase 3 topline results expected Q3 2026 for avexitide approval.
  • Potential $107.8 million revenue and $23.1 million earnings by 2029.
  • $317 million cash balance funds multiple clinical milestones through regulatory submissions.

What critics are saying

  • Relyvrio market withdrawal in April 2024 destroyed ALS revenue and credibility.
  • LUCIDITY Phase 3 failure in Q3 2026 halts pipeline pivot and accelerates cash burn.
  • PEGASUS Alzheimer's trial stalled since 2019; Eli Lilly's amyloid therapies dominate market.

What makes Amylyx Pharmaceuticals unique

  • Avexitide is first-in-class GLP-1 receptor antagonist for post-bariatric hypoglycemia.
  • AMX0035 targets dual pathways: endoplasmic reticulum stress and mitochondrial dysfunction.
  • Pipeline spans rare neurodegenerative diseases with high unmet medical needs.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Growth & Insights and Company News

Headcount

6 month growth

-1%

1 year growth

-3%

2 year growth

-12%
Business Wire
Apr 8th, 2026
Amylyx Pharmaceuticals to present at the 25th Annual Needham Virtual Healthcare Conference.

Amylyx Pharmaceuticals to present at the 25th Annual Needham Virtual Healthcare Conference. CAMBRIDGE, Mass.-(BUSINESS WIRE)-Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) ("Amylyx" or the "Company") today announced that management will present at the 25th Annual Needham Virtual Healthcare Conference. The corporate presentation will take place on Wednesday, April 15, 2026, at 8:45 a.m. ET. A live webcast of the presentation can be accessed under "Events and Presentations" in the Investor section of the Company's website, https://investors.amylyx.com/events-presentations, and will be available for replay for 90 days following the event. About Amylyx Pharmaceuticals At Amylyx, our mission is to usher in a new era of treating diseases with high unmet needs. Where others see challenges, we see opportunities that we pursue with urgency, rigorous science, and unwavering commitment to the communities we serve. We are currently focused on four investigational therapies across several endocrine conditions and neurodegenerative diseases in which we believe can make the greatest impact. For more information, visit amylyx.com and follow us on LinkedIn and X. For investors, please visit investors.amylyx.com. Contacts. Investors Lindsey Allen Amylyx Pharmaceuticals, Inc. +1 (857) 320-6244 [email protected] More News From Amylyx Pharmaceuticals, Inc. CAMBRIDGE, Mass.-( BUSINESS WIRE )-Amylyx Pharmaceuticals Announces Completion of Enrollment in Pivotal Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia... CAMBRIDGE, Mass.-( BUSINESS WIRE )-Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) ("Amylyx" or the "Company") today reported financial and business results for the fourth quarter and full year ended December 31, 2025. "2025 was a year of meaningful advancement for Amylyx's pivotal avexitide program in post-bariatric hypoglycemia, as well as progress across our broader pipeline," said Joshua Cohen and Justin Klee, Co-CEOs of Amylyx. "In 2026, our primary focus is on our Phase 3 LUCIDITY trial of av... CAMBRIDGE, Mass.-( BUSINESS WIRE )-Amylyx Pharmaceuticals to Participate in Upcoming March Investor Conferences...

Yahoo Finance
Mar 28th, 2026
Amylyx completes enrollment in Phase 3 trial of first-in-class therapy for post-bariatric hypoglycemia

Amylyx Pharmaceuticals has completed enrolment in LUCIDITY, its pivotal Phase 3 trial of avexitide for post-bariatric hypoglycaemia following Roux-en-Y gastric bypass surgery. The 16-week, double-blind, placebo-controlled study has randomised and dosed its final participant. The milestone positions Amylyx to potentially file for approval of a first-in-class GLP-1 receptor antagonist for a condition with no FDA-approved therapies. Topline results are expected in Q3 2026. Earlier trials showed consistent reductions in severe hypoglycaemic events. The company maintains a $317 million cash balance to support trial milestones but remains loss-making. Analyst forecasts project revenues of $107.8 million and earnings of $23.1 million by 2029, though estimates vary considerably.

Yahoo Finance
Mar 4th, 2026
Amylyx completes LUCIDITY Phase 3 recruitment, pivots to Avexatide and GLP-1 antagonist

Amylyx Pharmaceuticals has completed recruitment for its pivotal Phase 3 LUCIDITY trial of Avexatide for post-bariatric hypoglycemia and is shifting its core focus towards the drug whilst preparing for potential expedited regulatory submission once top-line data becomes available later this year. The company has also nominated AMX318, a GLP-1 antagonist, as a new development candidate. Trading at $14.11, Amylyx shares are up 23.6% year-to-date and 368.8% over one year, though down 60.7% over three years. With a 2025 net loss of $144.74 million and minimal revenue, Amylyx is streamlining legacy programmes and reallocating spending. The company has filed a universal shelf registration including $100.87 million tied to common stock, signalling potential future equity issuance.

Aktiencheck.de AG
Feb 18th, 2026
TCG Crossover takes 5.7% stake in Amylyx Pharmaceuticals

TCG Crossover has acquired a 5.7% stake in Amylyx Pharmaceuticals, according to recent regulatory filings. The investment firm, through its Fund II and associated entities, now holds 6,243,812 shares of the biotechnology company. The filing classifies this as a passive investment, indicating no current intention to influence corporate strategy or management. The stake is based on 109.8 million total shares outstanding as of last October. For Amylyx, securing backing from established institutional investors typically contributes to shareholder base stability. The investment suggests professional capital allocators view the company's development projects favourably. Future stock performance will primarily depend on clinical trial outcomes, regulatory milestones and data releases from the company's pipeline.

Yahoo Finance
Feb 1st, 2026
Amylyx co-CEO sells 138K shares for $1.9M to cover option exercise costs

Amylyx Pharmaceuticals Co-Chief Executive Joshua B Cohen exercised 200,000 stock options and sold 138,167 shares on 15-16 January for approximately $1.9 million. The sale was conducted to cover option costs and tax obligations, not as a discretionary decision. The transaction reduced Cohen's direct holdings by 3.93% to 3,379,465 shares, representing an estimated 4.07% insider ownership. The shares sold significantly exceeded his historical median sell size of 15,220 shares. Amylyx is a clinical-stage biotechnology company focused on neurodegenerative diseases and endocrine conditions. Its flagship therapy, AMX0035, has shown effectiveness in slowing ALS progression. The company's share price rose approximately 223% in 2025, with market capitalisation reaching $1.57 billion. It's also advancing avexitide, a phase three candidate for treating hypoglycemia.